Related Experiment Video
Updated: Jan 10, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Tumor-Agnostic Drug Development
Michael Offin1, Dazhi Liu1, Alexander Drilon1
1From the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract:
Therapies designed to target cancers that harbor specific molecular signatures have reshaped the landscape of oncologic drug development, and advances in next generation sequencing have led to an increase in the identification of these alterations across tumor types. Tumor-agnostic trial designs, such as the "basket trial," have been developed as an approach to study the efficacy of these treatments and increase patient access, especially for patients whose tumors carry these alterations infrequently. We review key aspects of these genomically enriched trial strategies and their impact on drug development and approval.
Insights
Targeted cancer therapies and next-generation sequencing are revolutionizing oncology. Tumor-agnostic basket trials improve access to these treatments for rare molecular alterations.
Area of Science:
- Oncology
- Genomics
- Clinical Trial Design
Background:
- Molecularly targeted therapies have transformed cancer treatment.
- Next-generation sequencing (NGS) increases identification of specific cancer alterations.
- Rare molecular alterations present challenges for traditional drug development.
Purpose of the Study:
- To review genomically enriched trial strategies.
- To discuss the impact of these trials on drug development and approval.
- To highlight the role of basket trials in studying targeted therapies.
Main Methods:
- Review of key aspects of tumor-agnostic trial designs.
- Analysis of the impact on oncologic drug development.
- Examination of patient access to novel therapies.
Main Results:
- Genomically enriched trials accelerate the study of targeted therapies.
- Basket trials facilitate investigation of treatments across diverse tumor types.
- These strategies increase patient access to precision oncology drugs.
Conclusions:
- Tumor-agnostic trials, like basket trials, are crucial for developing targeted cancer therapies.
- These innovative designs improve drug approval pathways.
- They enhance patient access to treatments for rare molecular alterations.
More Related Videos
Related Concept Videos
02:18Cancer
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...